Allergic Rhinoconjunctivitis
Stallergenes focuses on birch pollen-induced allergic rhinoconjunctivitis, with clinical interest in the management of seasonal nasal and eye symptoms in children and adolescents.
- Birch pollen allergy
- Rhinoconjunctivitis symptom control
- Pediatric allergy care
The sponsor’s research activity is centered on allergic disease affecting the upper airways and ocular tissues, with attention to symptom relief in young patients.
Respiratory Allergy
Its clinical research includes allergic airway disease linked to pollen exposure, reflecting interest in conditions that overlap with asthma in some patients.
- Seasonal pollen allergy
- Upper airway inflammation
- Asthma comorbidity
This area highlights the sponsor’s involvement in respiratory allergy management across paediatric and adolescent populations.
Allergen Immunotherapy
Stallergenes is active in allergen immunotherapy for birch pollen sensitisation, with a therapeutic focus on reducing allergic symptoms and the need for rescue medication.
- Birch pollen immunotherapy
- Allergy symptom reduction
- Rescue medication use
The sponsor’s trial portfolio reflects a specific interest in targeted treatment for pollen-driven allergic disease.
Paediatric and Adolescent Allergy
Clinical activity is directed toward paediatric and adolescent patients, with emphasis on allergic conditions that begin in early life and persist through school-age years.
- Children aged 5 to 17 years
- Adolescent allergy treatment
- Seasonal symptom burden
This patient group is central to the sponsor’s therapeutic interest in age-specific allergy care.
